Companies · Pharmaceuticals
CH-1202 GENEVA · Pharmaceuticals
Diligence memoA one-page analyst read on Relief Therapeutics Holding SA — recommendation, valuation, rhythm, risks.→Relief Therapeutics Holding SA looks fair against its niche peers and is dormant on financing cadence.
Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.
Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.
Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.
Relief Therapeutics Holding SA behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.
No named principal in this company's public records yet — see all operators below.
Explore how these operators interlock with other companies in the operator network.
Relief Therapeutics Holding SA is one of 1613 Pharmaceuticals companies tracked from CH-1202 GENEVA. By capital raised it ranks in the upper tier (ahead of 71% of sector peers), and in the upper tier by modeled valuation est..
Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.
As reported in public records reported — not modeled.
Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.
The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.
Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.
Round size and date are reported; the stage label is inferred from round size (latest is Series B — a $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.
Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.
Raised more than 71% of sector peers (real $). Modeled value above 77% of peers (estimate).
A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #36 of 61.
| Company | Stage | Raised · real | Value · est | vs peer med. |
|---|---|---|---|---|
| Evolus, Inc. | Series B | $40.5M | $1.4B | 2.74× |
| HOOKIPA Pharma Inc. | Series B | $37.4M | $1.3B | 2.57× |
| ESSA Pharma Inc. | Series B | $56.0M | $1.2B | 2.47× |
| Pieris Pharmaceuticals, Inc. | Series B | $102.1M | $1.1B | 2.20× |
| Amylyx Pharmaceuticals, Inc. | Series B | $65.1M | $1.0B | 2.06× |
| PassPort Technologies, Inc. | Series B | $30.0M | $1.0B | 2.06× |
| Savara Inc | Series B | $30.9M | $910.6M | 1.84× |
| InCarda Therapeutics, Inc. | Series B | $66.3M | $857.5M | 1.73× |
| Aceto Management, L.L.C. | Series B | $23.6M | $803.2M | 1.62× |
| GPI Finco (Canada) Inc. | Series B | $22.9M | $778.0M | 1.57× |
| Phosplatin Therapeutics LLC | Series B | $72.3M | $722.8M | 1.46× |
| Lannett Co Inc | Series B | $28.0M | $691.3M | 1.40× |
| Relief Therapeutics Holding SA this company | Series B | $27.1M | $365.1M | 0.74× |
Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.
| Stage | Amount · real | Announced | Post-money · est | Value · est | Conf. |
|---|---|---|---|---|---|
| Series A | $10.7M | 2021-03-11 | $48.8M | $244.1M | 90% |
| Series B | $16.4M | 2021-07-28 | $91.1M | $365.1M | 90% |
Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.
Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.
Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.
| Person | Role | Also runs | Tied since |
|---|---|---|---|
| Taneli Jouhikainen | — | 1 other | 2021-07 |
| Chris Stijnen | — | — | 2021-03 |
| Chris Stinjen | — | — | 2021-07 |
| Gilles Della Corte | — | — | 2021-03 |
| Jack Weinstein | — | — | 2021-03 |
| Paolo Galfetti | — | — | 2021-07 |
| Patrice Jean | — | — | 2021-07 |
| Raghuram Selvaraju | — | — | 2021-03 |
| Tom Plitz | — | — | 2021-07 |
Relief Therapeutics Holding SA is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.
Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.
| Company | Sector | Stage | Raised · real | Value · est | Why similar |
|---|---|---|---|---|---|
| Savara Inc. | Pharmaceuticals | Series B | $84.3M | $702.9M | network1 shared operator · same sector · same stage |
| Eton Pharmaceuticals, Inc. | Pharmaceuticals | Series B | $27.6M | $255.0M | same sector · same stage |
| Cullinan Mica Corp. | Pharmaceuticals | Series B | $26.6M | $174.5M | same sector · same stage |
| Exela Holdings Inc | Pharmaceuticals | Series B | $26.4M | $556.0M | same sector · same stage |
| Cxl Ophthalmics, Inc. | Pharmaceuticals | Series B | $26.4M | $370.1M | same sector · same stage |
| Skinmedica Inc | Pharmaceuticals | Series B | $26.2M | $569.9M | same sector · same stage |
| Woolsey Pharmaceuticals, Inc. | Pharmaceuticals | Series B | $28.3M | $436.6M | same sector · same stage |
| Avenacy Inc. | Pharmaceuticals | Series B | $26.0M | $157.1M | same sector · same stage |
Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.
| Company | Sector | Stage | Value · est | Match |
|---|---|---|---|---|
| Cure Pharmaceutical Holding Corp. | Pharmaceuticals | Series B | $343.2M | 79% |
| Alpha Pharm South African company. | — | — | — | 77% |
| Pharmapotheca A, LLC | Pharmaceuticals | Seed | $87.3M | 75% |
| Solaxa Inc. | Pharmaceuticals | Pre-Seed | $1.3M | 75% |
| Saghmos Therapeutics, Inc. | Pharmaceuticals | Seed | $133.1M | 75% |
| Bio South African company. | Biotech / Pharma | — | — | 74% |
| Cabinet Health P.B.C. | Pharmaceuticals | Series A | $124.0M | 74% |
| Response Pharmaceuticals, Inc. | Pharmaceuticals | Series A | $20.5M | 74% |
See where Relief Therapeutics Holding SA sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.
If you work at Relief Therapeutics Holding SA, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.
Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.